Roivant Sciences Ltd. $ROIV Shares Purchased by New York State Teachers Retirement System

New York State Teachers Retirement System raised its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) by 15.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 255,921 shares of the company’s stock after buying an additional 34,000 shares during the period. New York State Teachers Retirement System’s holdings in Roivant Sciences were worth $3,872,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. CWM LLC boosted its holdings in Roivant Sciences by 44.6% in the second quarter. CWM LLC now owns 2,984 shares of the company’s stock valued at $34,000 after purchasing an additional 920 shares in the last quarter. Osaic Holdings Inc. lifted its position in Roivant Sciences by 204.2% in the second quarter. Osaic Holdings Inc. now owns 5,783 shares of the company’s stock valued at $65,000 after acquiring an additional 3,882 shares during the last quarter. UMB Bank n.a. boosted its stake in Roivant Sciences by 42.0% in the second quarter. UMB Bank n.a. now owns 5,883 shares of the company’s stock valued at $66,000 after acquiring an additional 1,740 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Roivant Sciences by 22.9% during the second quarter. GAMMA Investing LLC now owns 7,978 shares of the company’s stock worth $90,000 after purchasing an additional 1,485 shares during the last quarter. Finally, Rossby Financial LCC purchased a new position in shares of Roivant Sciences during the second quarter worth about $113,000. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Roivant Sciences Trading Down 0.7%

NASDAQ:ROIV opened at $23.13 on Friday. Roivant Sciences Ltd. has a 12-month low of $8.73 and a 12-month high of $23.91. The stock’s 50 day simple moving average is $21.51 and its 200-day simple moving average is $16.63. The firm has a market cap of $16.09 billion, a P/E ratio of -41.30 and a beta of 1.22.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ROIV. Leerink Partners boosted their target price on Roivant Sciences from $29.00 to $32.00 and gave the company an “outperform” rating in a report on Monday, December 15th. Wall Street Zen raised Roivant Sciences from a “strong sell” rating to a “hold” rating in a report on Sunday, November 16th. HC Wainwright raised their target price on shares of Roivant Sciences from $23.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. The Goldman Sachs Group upped their price target on shares of Roivant Sciences from $24.00 to $33.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Finally, Guggenheim reiterated a “buy” rating and set a $28.00 price target on shares of Roivant Sciences in a research note on Thursday, December 18th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $25.19.

Insider Transactions at Roivant Sciences

In other Roivant Sciences news, Director Daniel Allen Gold sold 1,300,000 shares of the company’s stock in a transaction on Wednesday, November 19th. The shares were sold at an average price of $20.23, for a total transaction of $26,299,000.00. Following the completion of the transaction, the director owned 18,047,727 shares in the company, valued at approximately $365,105,517.21. This represents a 6.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Vivek Ramaswamy sold 1,975,858 shares of the firm’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $21.96, for a total transaction of $43,389,841.68. Following the completion of the sale, the insider owned 36,350,621 shares of the company’s stock, valued at $798,259,637.16. This trade represents a 5.16% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 12,332,392 shares of company stock worth $266,393,645 over the last quarter. 10.80% of the stock is currently owned by corporate insiders.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.